U.S. pharmaceutical concern Johnson & Johnson on
Tuesday reported a fall in third quarter net income to $3 billion, or $1.15 a share, down from $3.2 billion in the same
period last year.
The 7.3 percent decline was attributed to increased research and production costs.
Revenues rose to $17.1 billion, a rise of 6.5 percent over the same quarter last year. The stronger dollar hurt the value of foreign sales, which otherwise would have grown 10.8 percent over the same quarter last year, the company said.
Most Popular Stories
- Hezbollah Chief's Assassination Claimed by Sunni Group
- Allstate Seeks to Invest in Minority Firms
- SpaceX's Satellite Launch Is 'Game-Changer'
- Latin Music Conference Turns 25
- U.S. Growth Stayed Steady During Shutdown, Fed Says
- Newtown Massacre Heard on 911 Recordings
- Climate Change Early Warning System Urged
- Guardian Pressured to Stop NSA Stories: Editor
- New Home Sales Shoot up 25 Percent in October
- Reid Confident Congress to Pass Immigration Bill